Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Prevention of Postpartum Depression After Cesarean Section
ChiCTR2400085495Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postpartum depression (PPD) comparing Esketamine 0.25 mg/kg arm with Normal saline placebo arm (2 arms). Primary endpoint: Incidence of postpartum depression at 6 weeks after cesarean section. Started Jun 2024; status: recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ChiCTR2400085495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085495.